Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs.


Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
14 12 2021
Historique:
received: 01 10 2020
revised: 01 11 2021
accepted: 01 11 2021
pubmed: 4 12 2021
medline: 4 3 2022
entrez: 3 12 2021
Statut: ppublish

Résumé

Platelet transfusions are critical for severe thrombocytopenia but depend on blood donors. The shortage of donors and the potential of universal HLA-null platelet products have stimulated research on the ex vivo differentiation of human pluripotent stem cells (hPSCs) to platelets. We recently established expandable immortalized megakaryocyte cell lines (imMKCLs) from hPSCs by transducing MYC, BMI1, and BCL-XL (MBX). imMKCLs can act as cryopreservable master cells to supply platelet concentrates. However, the proliferation rates of the imMKCLs vary with the starting hPSC clone. In this study, we reveal from the gene expression profiles of several MKCL clones that the proliferation arrest is correlated with the expression levels of specific cyclin-dependent kinase inhibitors. Silencing CDKN1A and p53 with the overexpression of MBX was effective at stably inducing imMKCLs that generate functional platelets irrespective of the hPSC clone. Collectively, this improvement in generating imMKCLs should contribute to platelet industrialization and platelet biology.

Identifiants

pubmed: 34861163
pii: S2213-6711(21)00554-3
doi: 10.1016/j.stemcr.2021.11.001
pmc: PMC8693651
pii:
doi:

Substances chimiques

BMI1 protein, human 0
Cyclin-Dependent Kinase Inhibitor p21 0
Proto-Oncogene Proteins c-myc 0
Tumor Suppressor Protein p53 0
bcl-X Protein 0
Polycomb Repressive Complex 1 EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2861-2870

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Références

J Biol Chem. 2003 Aug 29;278(35):32507-16
pubmed: 12748190
Science. 1998 Nov 20;282(5393):1497-501
pubmed: 9822382
Stem Cell Reports. 2020 Jan 14;14(1):49-59
pubmed: 31883921
J Exp Med. 2010 Dec 20;207(13):2817-30
pubmed: 21098095
Cell. 2018 Jul 26;174(3):636-648.e18
pubmed: 30017246
PLoS One. 2013 Jun 21;8(6):e66464
pubmed: 23805223
Blood. 2008 Jun 1;111(11):5298-306
pubmed: 18388179
Cell Stem Cell. 2014 Apr 3;14(4):535-48
pubmed: 24529595
Science. 2002 Apr 19;296(5567):550-3
pubmed: 11910072
Cancer Cell. 2003 Oct;4(4):311-9
pubmed: 14585358
Blood. 2018 Jan 18;131(3):277-288
pubmed: 29191915
Methods Mol Biol. 2012;788:205-17
pubmed: 22130710
EMBO Rep. 2014 Oct;15(10):1062-8
pubmed: 25141863
Cancer Res. 2017 Jun 1;77(11):3092-3100
pubmed: 28377455
Oncol Res. 2012;20(2-3):81-91
pubmed: 23193914
PLoS One. 2016 Oct 14;11(10):e0163885
pubmed: 27741251

Auteurs

Masamitsu Sone (M)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Sou Nakamura (S)

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Sachiko Umeda (S)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Harumi Ginya (H)

Megakaryon Corporation, Kyoto, Japan.

Motohiko Oshima (M)

Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Maria Alejandra Kanashiro (MA)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Sudip Kumar Paul (SK)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Kanae Hashimoto (K)

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Emiri Nakamura (E)

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Yasuo Harada (Y)

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Kyoko Tsujimura (K)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Atsunori Saraya (A)

Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.

Tomoyuki Yamaguchi (T)

Laboratory of Regenerative Medicine, Tokyo University of Pharmacy and Life Science, Tokyo, Japan.

Naoshi Sugimoto (N)

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.

Akira Sawaguchi (A)

Ultrastructural Cell Biology, Department of Anatomy, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Atsushi Iwama (A)

Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Koji Eto (K)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. Electronic address: kojieto@cira.kyoto-u.ac.jp.

Naoya Takayama (N)

Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. Electronic address: tnaoya19760517@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH